RAMMF - RAMM pharma starts trials of Nettavet cannabinoid formulation

RAMM Pharma (RAMMF) announces that it has initiated clinical trials studying the efficacy of its proprietary NettaVet pet cannabinoid formulation for the treatment of four pathologies in animals.The trials will be conducted in partnership with Universidad de la Republica de Uruguay in collaboration with leading international experts at Montreal University (Canada), University of Buenos Aires (Argentina), São Paulo State University (Brazil) and University of Barcelona (Spain).Aims to evaluate the efficacy of NettaVet for the treatment of Chronic Osteoarthritis pain in dogs (Cannis familiaris), Chronic Osteoarthritis pain in horses (Equus caballus), Allergic Dermatitis in dogs (Cannis familiaris) and Anxiety in dogs (Cannis familiaris).

For further details see:

RAMM pharma starts trials of Nettavet cannabinoid formulation